SCHEMBL144412

SCHEMBL144412

Cc1cc(C(=O)N2CCC[C@H]2CN2CCCC2)c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)[nH]1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 13/20 0.80
KDR P35968 10/20 0.80
PDGFRB P09619 8/20 0.80
YES1 P07947 8/20 0.80
FGFR1 P11362 8/20 0.80
LCK P06239 7/20 0.80
MET P08581 5/20 0.80
KIT P10721 2/20 0.80
CDK2 P24941 2/20 0.80
PTK2B Q14289 2/20 0.80
MEN1 O00255 2/20 0.80
KMT2A Q03164 2/20 0.80
TDP1 Q9NUW8 2/20 0.80
PLK4 O00444 1/20 0.80
RIOK3 O14730 1/20 0.80
CASK O14936 1/20 0.80
GAK O14976 1/20 0.80
DCLK1 O15075 1/20 0.80
EPHB6 O15197 1/20 0.80
MAP3K13 O43283 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pha-665752 SCHEMBL93656 0.89 KDR (1.00) SRCKDRPDGFRBYES1FGFR1
Pha-665752 SCHEMBL93657 0.89 KDR (1.00) SRCKDRPDGFRBYES1FGFR1
Pha-665752 SCHEMBL93654 0.89 KDR (1.00) SRCKDRPDGFRBYES1FGFR1
Pha-665752 SCHEMBL29376386 0.89 KDR (1.00) SRCKDRPDGFRBYES1FGFR1
Pha-665752 SCHEMBL93655 0.89 KDR (1.00) SRCKDRPDGFRBYES1FGFR1
Pha-665752 SCHEMBL140412 0.89 KDR (1.00) SRCKDRPDGFRBYES1FGFR1
Pha-665752 SCHEMBL15639803 0.88 KDR (0.99) SRCKDRPDGFRBYES1FGFR1
Pha-665752 SCHEMBL15639801 0.88 KDR (0.99) SRCKDRPDGFRBYES1FGFR1
SCHEMBL23691031 0.86 KDR (0.94) SRCKDRPDGFRBYES1FGFR1
SCHEMBL143795 0.85 KDR (0.93) SRCKDRPDGFRBYES1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 SRC 2611/4885KDR 1077/4885PDGFRB 467/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 SRC 2611/4885KDR 1077/4885PDGFRB 467/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 SRC 75/4885KDR 398/4885PDGFRB 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.